GeoVax completes patient enrollment in Phase 1/2 trial of HIV/AIDS therapeutic vaccine
07:38 EST 11 Jan 2013 | Pharmaceutical Business Review
GeoVax Labs has completed enrolling nine patients in Phase 1/2 trial evaluating the safety, immunogenicity and ability of its DNA/MVA vaccine, the HIV/AIDS therapeutic vaccine.
Original Article: GeoVax completes patient enrollment in Phase 1/2 trial of HIV/AIDS therapeutic vaccine
More From BioPortfolio on "GeoVax completes patient enrollment in Phase 1/2 trial of HIV/AIDS therapeutic vaccine"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
